AUTHORS
Wenqiang Yan, Chenxing Du, MD2, Rui Lv, MD3, Hesong Zou4, Shuaishuai Zhang5, Shuhui Deng6, Lu-Gui Qiu, PhD7, Gang An, MD8
AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, Tianjin, China
ABSTRACT
Background: We previously reported the initial results of CAREMM-002 (NCT05979363), a prospective phase 2 study evaluating frontline BCMA CAR T-cell therapy in newly diagnosed, transplant-ineligible primary plasma cell leukemia. Here, we present updated efficacy and safety data with expanded enrollment and longer follow-up. Primary plasma cell leukemia remains an ultra-high-risk plasma cell neoplasm with poor outcomes, and prospective data for transplant-ineligible patients are limited.
Methods: CAREMM-002 is an investigator-initiated, open-label, single-arm phase 2 study. Eligible patients had newly diagnosed primary plasma cell leukemia and were deemed ineligible for autologous stem cell transplantation because of age, frailty, comorbidities, or repeated stem-cell mobilization failure. Patients received 3–4 cycles of VRd-based induction, followed by lymphodepletion and a single infusion of BCMA CAR T cells, then consolidation and maintenance. Primary endpoints were MRD negativity post-infusion and safety.
Results:
As of May 16, 2026, 22 patients were enrolled. Median age was 68 years (range, 54–75), 7 patients were aged ≥70 years, 11 were male, and 15 were CGS high-risk. Nineteen patients had received BCMA CAR T-cell infusion; 10 were receiving maintenance, 6 were receiving consolidation, and 3 remained in early post-infusion follow-up.
Eighteen patients with available post-infusion response assessment were included in the current efficacy and safety analysis. The overall response rate was 100%, with stringent complete response in 16 of 18 patients (88.9%). All 18 patients (100%) achieved NGF-MRD negativity at 10^-5. At a median follow-up of 18.0 months, median progression-free survival, overall survival, and duration of remission were not reached. The estimated 12- and 24-month progression-free survival rates were 100% and 87.5%, respectively. Only one patient relapsed at 23.1 months after enrollement, and no death were observed.
Safety remained manageable. The most common grade ≥3 hematologic adverse events were lymphopenia in 18 patients (100%), leukopenia in 16 (88.9%), neutropenia in 14 (77.8%), thrombocytopenia in 5 (27.8%), and anemia in 4 (22.2%). Cytokine release syndrome (CRS) occurred in 13 patients (72.2%), all grade 1–2, with a median onset of 3 days and median duration of 3 days. No immune effector cell-associated neurotoxicity syndrome was observed.
Conclusion: With expanded enrollment and longer follow-up, frontline BCMA CAR T-cell therapy continued to induce deep and durable responses with manageable toxicity in newly diagnosed, transplant-ineligible primary plasma cell leukemia. These updated CAREMM-002 data support further evaluation of early BCMA-directed cellular therapy for this ultra-high-risk population.
DISCLOSURES
Wenqiang Yan: No relevant conflicts of interest to declare.